Sirona Biochem Hires New York-based Investor Relations Firm Consulting for Strategic Growth 1

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 22, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB), announced today it has hired Consulting for Strategic Growth 1 (CFSG1), an investor relations and corporate development firm based in New York City. CFSG1 has been hired to increase awareness of Sirona Biochem in the U.S. marketplace.

"Now that we are trading on the OTCQX in the U.S., it's important to have strong, credible U.S. representation to communicate the value of Sirona Biochem and the excellent progress we have been making," said Neil Belenkie, Sirona Biochem Chief Executive Officer. "CFSG1 has proven expertise in taking emerging growth companies to the forefront of the American investor marketplace and we look forward to working with their team to share Sirona Biochem's story."

Stan Wunderlich, Chairman and CEO of CFSG1, commented, "Sirona Biochem is changing the nature of carbohydrate-based chemistry and is delivering new, powerful compounds that have the potential to change the landscape of the drug, cosmetic and biochemistry industries. We are excited to be a partner in this venture and believe a great opportunity exists for this company in the public arena."

Sirona Biochem will pay CFSG1 US$8,750.00 per month during a six month term starting February 1, 2013 and, subject to approval by Sirona Biochem's Board of Directors, will issue 750,000 stock options to CFSG1 at an exercise price of $0.12 per share (the "Options"), subject to vesting.

Consulting for Strategic Growth 1 (CFSG) is a leader in reverse mergers, investor and media relations and corporate development. The formation of capital for early-growth stage companies, domestic and international, is one of our core businesses. In recent years, CFSG has helped raise more than $90 million for domestic and international companies new to the U.S. public marketplace. With decades of hands-on corporate development experience and broad personal outreach in the private and public investment communities, we place our clients in front of the right decision-makers, market makers and financial gatekeepers - the ones who know your industry, care about your business, and can address your financial needs.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit www.sironabiochem.com.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.